non-enzymatic actions and the overall significance of DPP-4 for normal physiological regulation in humans and for the pathogenesis of metabolic disease are still largely unknown, targeting the catalytic activity has been harnessed pharmacologically, and DPP-4 inhibitors now play an important part in the therapy of T2DM
Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: A 52-week prospective real-life study
Formulated with 0.9% benzyl alcohol, this solution helps inhibit microbial growth, allowing for multi-dose use under proper laboratory handling conditions
Evaluation of abnormal liver-enzyme results in asymptomatic patients
FOXO4-DRI functions as a competitive inhibitor, displacing p53 from FOXO4, thereby allowing the selective clearance of senescent cells (2, 9)
Also, in patients with rectal cancer, infusing a solution enriched in Leu, Ile and Val led to an increase in the number of CD4+ (Th) cells in blood, and led to an increased ratio of CD4+/CD8+ (cytotoxic T) cells in the blood (103)
